Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015
Date of Board Meeting / Approval: 05th August, 2026
Audit Opinion: Clean (Unaudited results with a limited review report. No qualifications or modifications noted.)
Auditor’s Comment: The statutory auditors, P. Murali & Co., issued a clean limited review report stating that nothing has come to their attention to believe the financial results contain any material misstatement.
Key Financial Highlights [₹ in lakhs]
Standalone Results:
Revenue from Operations: ₹1,558.37 (Q1 FY27) vs ₹1,670.82 (Q1 FY26) [YoY decrease of ₹112.45 lakh]
Total Income: ₹1,649.99 (Q1 FY27) vs ₹1,717.04 (Q1 FY26)
EBITDA: Not disclosed
Net Profit/(Loss): Net Loss of ₹(125.32) (Q1 FY27) vs Net Profit of ₹19.49 (Q1 FY26)
EPS: Basic & Diluted EPS of ₹(0.23) (Q1 FY27) vs ₹0.04 (Q1 FY26)
Other Equity: Not specified in the standalone results table
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Consolidated Results:
Revenue from Operations: ₹7,074.21 (Q1 FY27)
Total Income: ₹7,968.97 (Q1 FY27)
EBITDA: Not disclosed
Net Profit: ₹129.74 (Q1 FY27)
EPS: Basic & Diluted EPS of ₹0.24 (Q1 FY27)
Other Equity: Not specified in the consolidated results table
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Material Change: The standalone performance shows a material deterioration, moving from a net profit in Q1 FY26 to a net loss in Q1 FY27.
Segment-wise Performance:
The operating segment is identified as "Specialized Wholesale." The Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, segment-wise disclosure is not applicable.
Corporate Actions:
Not Specified
Other Significant Information:
Progress of Pharmaceutical Formulation Plant at Jadcherla, Hyderabad:
- The board noted the progress of the company's first pharmaceutical formulation manufacturing facility.
- Commercial production has successfully commenced with two initial products: Paracetamol Tablets 500mg and Piroxicam Capsules 20mg.
- The company has received manufacturing product permissions for an additional 29 products, taking the total approved commercial product portfolio to 31 products.
- Raw materials for these products have started arriving, and commercial production will be initiated progressively.
- A WHO-GMP audit of the facility was conducted in July 2026 through a joint inspection by CDSCO and the State FDA.
- The audit observation report has been received, and the company has submitted its Corrective and Preventive Action (CAPA) response.
- The company is on track for obtaining WHO-GMP certification.
The Board expressed satisfaction with the progress achieved.